IHMT-TRK-284(Compound 34)是一种有效的、具有口服活性的 type II TRK kinase 抑制剂,对 TRKA、B、C 的 IC50 值分别为 10.5、0.7 和 2.6 nM,在激酶组中表现出良好的选择性,并具有良好的体内抗肿瘤效果。
产品编号: MS-P09885 CAS No.: 2416844-79-4
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

IHMT-TRK-284(Compound 34)是一种有效的、具有口服活性的 type II TRK kinase 抑制剂,对 TRKA、B、C 的 IC50 值分别为 10.5、0.7 和 2.6 nM,在激酶组中表现出良好的选择性,并具有良好的体内抗肿瘤效果。

生物实验数据

生物活性 IHMT-TRK-284 (Compound 34) is a potent, orally active type II TRK kinase inhibitor with IC50 values of 10.5, 0.7, and 2.6 nM against TRKA, B, and C, respectively, demonstrating good selectivity across the kinome and favorable in vivo antitumor efficacy.
IC50 & Target PDGFRβ:95.7 nM, TrkB:0.7 nM, c-Kit:2167 nM, Abl-1:83.6 nM, PDGFRα:24.2 nM, TrkC:2.6 nM, TrkA:10.5 nM, CSF1R:1.2 nM
体外研究
(In Vitro)

IHMT-TRK-284 (Compound 34) (0-10 µM, 72 h) shows antiproliferative effects against BaF3 cells, a panel of kinase transformed BaF3 cells, and KM-12-LUC cells.
IHMT-TRK-284 (0-10 µM, 24 h) induces apoptosis and arrests the cell cycle into G0/G1 phase in KM-12-LUC cells.
IHMT-TRK-284 exerts its inhibitory effect to the colon cancer cells through on-target inhibition of TRK.
IHMT-TRK-284 could overcome drug resistant mutants including V573M and F589L in the ATP binding pocket as well as G667C/S in the DFG region.
IHMT-TRK-284 shows selectivity over VEGFR2 kinase.

Cell Proliferation Assay

Cell Line: BaF3 cells, a panel of kinase transformed BaF3 cells, and KM-12-LUC cells
Concentration: 0-10 µM
Incubation Time: 72 h
Result: Showed antiproliferative effects against BaF3 cells, a panel of kinase transformed BaF3 cells, and KM-12-LUC cells. GI50 for KM-12-LUC cells was 0.002 µM.
Antiproliferative effects of IHMT-TRK-284 against a panel of kinase transformed BaF3 cells.
Target BaF3-TEL-ABL BaF3-TEL-CSF1R BaF3-TEL-KIT BaF3-TEL-PDGFRα BaF3-TEL-PDGFRβ BaF3-TEL-TRKA BaF3-TEL-TRKB BaF3-TEL-TRKC
GI50 (nM) 411.1 4 923.2 1.7 1.4 8.5 8.2 27.3

Antiproliferative effects of IHMT-TRK-284 against a panel of TRKs wt/mutants transformed BaF3 cells (n = 3).
Showed antiproliferative effects with GI50s of 1.4 ± 0.011, 0.007 ± 0.001, 0.003 ± 0.001, 0.004 ± 0.001, 0.194 ± 0.013, 0.034 ± 0.002, 0.002 ± 0.001 μM against BaF3, BaF3-LMNA-TRKA, BaF3-LMNA-TRKA-V573M, BaF3-LMNA-TRKA-F589L, BaF3-LMNA-TRKA-G595R, BaF3-LMNA-TRKA-G667C, BaF3-LMNA-TRKA-G667S cells, respectively.

Western Blot Analysis

Cell Line: BaF3-TEL-TRKA, BaF3-TEL-TRKB, BaF3-TEL-TRKC, BaF3-LMNATRKA-V573M, BaF3-LMNA-TRKA-F589L, BaF3-LMNA-TRKA-G595R, BaF3-LMNA-TRKA-G667C/S, and KM-12-LUC cells
Concentration: 0, 0.01, 0,03, 0.1, 0.3, 1, 3, and 10 µM
Incubation Time: 2 h
Result: In transformed BaF3 cells: Inhibited the phosphorylation of TRKA Y490 (EC50 = 0.026 µM) and corresponding tyrosine residues TRKB Y515 (EC50 = 0.069 µM) and TRKC Y516 (EC50 = 0.029 µM); potently inhibited the phosphorylation of Y490 in V573M, F589L, and G667C/S mutants with EC50s of 0.013 µM, 0.021 µM, 0.067 µM, and 0.074 µM respectively. In KM-12-LUC cells: Blocked the phosphorylation of TRKA Y490 at the concentration of 0.01 µM; remarkably inhibited the phosphorylation of downstream signaling mediators AKT T308/S473 and ERK1/2 (T202/Y204) (EC50 less than 0.03 µM).

Apoptosis Analysis

Cell Line: KM-12-LUC cells
Concentration: 0, 0.01, 0,03, 0.1, 0.3, 1, 3, and 10 µM
Incubation Time: 24 h
Result: Induced dose-dependent cell apoptotic death.

Cell Cycle Analysis

Cell Line: KM-12-LUC cells
Concentration: 0, 0.01, 0,03, 0.1, 0.3, 1, 3, and 10 µM
Incubation Time: 24 h
Result: Arrested the cell cycle into G0/G1 phase.
体内研究
(In Vivo)

IHMT-TRK-284 (Compound 34) (40 and 80 mg/kg; p.o.; daily, 10 days) shows good in vivo PK and antitumor efficacy properties.

Animal Model: Four-week old female nu/nu mice, one million BaF3-TELTRKA, BaF3-TEL-TRKB, BaF3-TEL-TRKC, BaF3-LMNA-TRKA-F589L, BaF3-LMNA-TRKA-G667S, and five million KM-12-LUC cells in DMEM medium were formulated as a 1:1 mixture with matrigel and injected into the subcutaneous space on the right flank of nu/nu mice
Dosage: 40 mg/kg and 80 mg/kg
Administration: Daily oral gavage, 10 days
Result: Dose-dependently inhibited the BaF3-TEL-TRKA, BaF3-TEL-TRKB, and BaF3-TEL-TRKC tumor progression with TGI (tumor growth inhibition) of 68%, 93%, and 58%. Dose-dependently inhibited the tumor progression and exhibited the TGI of 93% at 40 mg/kg/day and 95% at 80 mg/kg/day in KM-12-LUC cells inoculated xenograft mouse model. Potently inhibited the tumor growth with TGI values of 88% and 89% respectively at 80 mg/kg dosage in BaF3- LMNA-TRKA-F589L and BaF3-LMNA-TRKA-G667S cells.
Animal Model: Mice, sprague dawley rats, and beagle dogs
Dosage: 1 mg/kg and 10 mg/kg
Administration: Intravenous injection and oral administration (Pharmacokinetic Analysis)
Result: Pharmacokinetic study of IHMT-TRK-284 in mice, sprague dawley rats, and beagle dogsa
Parameter Mice
i.v. (1 mg/kg)
Mice
p.o. (10 mg/kg)
Rats
i.v. (1 mg/kg)
Rats
p.o. (10 mg/kg)
Beagle Dogs
i.v. (1 mg/kg)
Beagle Dogs
p.o. (10 mg/kg)
AUC(0-t)
(ng/mL*h)
748 1431 393 952 323 464
Tmax (h) 0.033 1.5 0.03 4.7 0.08 4.3
T1/2 (h) 2.6 3.4 2.7 2.5 0.03 11.8
Vz (mL/kg) 4934 31567 9682
分子量

473.59

Formula

C25H27N7OS

CAS 号

2416844-79-4

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
Data Sheet (541 KB) 产品使用指南 (1538 KB)
参考文献
  • . Beilei Wang, et al. Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistan  [Content Brief]

  • . Beilei Wang, et al. Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistan

IHMT-TRK-284 相关分类

  • Cancer
  • 肿瘤靶向治疗 肿瘤耐药 肿瘤代谢与转移
  • Neuronal Signaling Protein Tyrosine Kinase/RTK Apoptosis
  • Trk Receptor c-Fms PDGFR Bcr-Abl c-Kit Apoptosis
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2

化学信息

CAS No. 2416844-79-4

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础

  • 客服

    2851296953

    18923798467

    微信洽谈